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In-Strand Metallated Nucleic Acids – Novel 
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Abstract: Synthetic strategies have been developed for the preparation of in-chain metallated oligonucleotides, in 
which the oligonucleotide sequence is interrupted by a metal-containing motif. In our work, oligopyridine metal-
binding domains are used and approaches are outlined using both labile and non-labile metal centres.
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deleting damaged nucleic acid and for tar-
geting the nucleic acids of specific patho-
genic species. In a wider sense, DNA and 
RNA are information-storage molecules 
par excellence. They represent the proof 
of concept for molecule-based informa-
tion storage systems and give a hint at the 
density of information which may be stored 
in molecule-based computing systems and 
clues as to the technologies that must be de-
veloped for read–write processes involving 
such soft storage devices [1].
Our interests in nucleic acids originate 
in our ongoing research in supramolecu-
lar chemistry and nanoscale devices and 
are expressed in a synthetic programme 
leading to the preparation of nucleic acids 
in which metal complexes are covalently 
linked to the oligonucleotide backbone. In 
this article, we present a brief overview of 
the literature relating to such species and 
some aspects of our own work in which 
metal complexes are incorporated into the 
backbone of the nucleotide to give in-chain 
metallated species.
Nucleic Acids and Metal Ions
In biology, nucleic acids are intimately 
associated with metal ions, whether they 
simply act as counterions or in more spe-
cific interactions with species such as 
magnesium and manganese in phosphate 
metabolism [2]. Recently, metal complexes 
which interact directly with nucleic acids 
and bind to them have been used as thera-
peutics, particularly in cancer chemother-
apy [3]. Current and projected therapeutic 
applications of metal-containing drugs that 
target nucleic acids have a particular em-
phasis upon the recognition of specific se-
quences or genes, by covalently modifying 
a site within the gene, impeding or altering 
the transcription of the nucleic acid, or by 
causing hydrolysis of the nucleic acid. It is 
a single step from targeting specific genes 
within a nucleic acid to developing an anti-
sense methodology, in which single strand 
oligonucleotides or nucleic acids are actu-
ally used as therapeutics. Concurrent with 
the development and optimisation of thera-
peutics that target or are based upon nucleic 
acids, is the utilisation of information from 
the human genome project in general and 
the need to characterise specific nucleotide 
sequences in the context of PCR methods. 
These latter considerations have led us and 
others to consider unnatural bioconstructs 
in which metal centres are incorporated 
within an oligonucleotide chain [4]. We 
emphasise that this approach is fundamen-
tally different to those based upon the in-
teraction of discrete metal complexes with 
nucleic acids [5] or of that in which metal-
containing functionality is appended to the 
backbone of a nucleotide or nucleic acid 
or is attached to a 3ʹ- or 5ʹ-terminal [4]. 
The strategy is conceptually similar to that 
which has been used for the metal-directed 
synthesis of artificial DNA-arrays, such as 
triangles, by the self assembly of self-com-
plementary sequences functionalised with 
metal-binding domains [6].
Strategy
The basic strategy is presented in Fig. 
1: formally, two nucleotide sequences are 
required, each of which is terminated with 
a metal-binding domain. The metal-bind-
ing domain of choice for our work is an 
oligopyridine such as 2,2ʹ:6,2ʹʹ-terpyridine 
(tpy), 2,2ʹ-bipyridine (bpy) or 1,10-phenan-
throline (phen) (Fig. 2) which have well-
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Introduction
Nucleic acids are fundamental components 
of living systems that act as the genetic 
information pool for individuals and by 
extension for species and the entire bio-
sphere. Apart from the inherent chemical 
interest in nucleic acids as supramolecules 
and the desire to understand their precise 
roles and regulation in the development of 
individual organisms, there are compelling 
medical and socio-economic reasons for 
their study. Numerous disease states are ge-
netically linked, are associated with nucleic 
acid damage or are a direct consequence of 
invasion of the parent organism by other 
pathogenic organisms whose behaviour and 
action is controlled by their own nucleic ac-
ids. From a medical view-point, it is a high 
priority to develop methods for switching 
individual genes on or off, for detecting and 
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established coordination chemistry with 
almost every metal in the periodic table. 
These metal-binding domains have already 
been used for the attachment of pendant 
iron [7], europium [8], copper [9] and ru-
thenium [10] functionality. The approach 
is basically an antisense [11] or antigene 
[12] one, in which the metallated sequence 
is complementary to the target nucleotide 
or nucleic acid. We considered strategies 
involving both labile and non-labile metal 
ions. With labile metal ions (top route, 
Fig. 1), the two individual sequences are 
functionalised and allowed to react with 
the metal ion of choice, with a subsequent 
hybridisation step. The advantages and dis-
advantages of this strategy are presented 
later in this article. In our initial work, we 
adopted a methodology based upon ki-
netically inert ruthenium(II) centres which 
could be incorporated into an oligonucle-
otide sequence using standard solid phase 
methods (Fig. 1, lower route). 
Synthesis of Bioconstructs with 
Kinetically Inert Metal Ions
We chose the kinetically inert 
{Ru(tpy)2}
2+ motif (tpy = 2,2ʹ:6ʹ,2ʹʹ-terpy-
ridine) for our initial studies as this is 
topologically linear and has well-defined 
electrochemical, spectroscopic and photo-
physical properties which will both allow 
facile detection of the new bioconstructs 
and might allow specific metal-mediated 
chemistry (hydrolysis, photocleavage etc.) 
within the complementary strand after 
hybridisation – in other words the site of 
incorporation of the metal-containing unit 
can be used to target a specific sequence or 
gene within the complementary DNA. Our 
synthetic method of choice was phospho-
ramidite chemistry at a solid support. The 
{Ru(tpy)2}
2+ unit could be incorporated 
in a single step, but this carries with it the 
necessity of preparing asymmetrically di-
functionalised (one side protected, one side 
activated) complexes for incorporation into 
the solid-phase synthesis. Furthermore, to 
have a metallated strand complementary to 
a natural sequence, it is necessary to attach 
one of the tpy domains to the 3ʹ-position of 
a nucleotide and the other to the 5ʹ-posi-
tion of the other nucleotide. Although we 
have used this route, we have found it to be 
low-yielding and very sensitive to environ-
mental effects and have developed instead 
a highly efficient linear method (Fig. 3) 
in which the need for the difunctionalised 
complex is obviated. Using this route we 
obtain ruthenaoligonucleotides of generic 
structure 5ʹ-S1COCH2CH2OCH2CH2Otpy
RutpyOCH2CH2OCH2CH2OS2-3ʹ (I: S1 = 
TTTTTCTC S2 CTCTCT, II: S1 = TTCT-
TCT S2 CTCTCT, III: S1 = TTCTTC S2 
CTCTCT) in yields of 90–95%. The new, 
N N
N
NN
NN
2,2'-bipyridine, bpy
2,2':6',2"-terpyridine, tpy
1,10-phenanthroline, phen
Fig. 2. Ligand structures
Fig. 1. Two approaches to the preparation of in-chain metallated 
oligonucleotides. In the upper route an oligonucleotide bearing a terminal 
metal-binding domain (black bar) is prepared and then reacted with a labile 
metal centre, whereas in the lower route a kinetically inert metal complex is 
inserted in a stepwise manner.
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orange, oligonucleotides show the expected 
MLCT absorption at 484 nm, show parent 
ions in their MALDI-TOF mass spectra 
and are pure by HPLC and capillary elec-
trophoresis analysis.
What properties do these new ruthena-
oligonucleotides have? In general the melting 
points are lower than the best model native 
sequences, for example the three nucleotides 
I, II, and III in the presence of the comple-
mentary 3’-AAA-AAG-AGA-GAG-AGA-5ʹ 
RNA have melting points of 34.3, 23.3 and 
23.3 °C respectively, whereas wild-type 5ʹ-
TTT-TTC-TCT-CTC-TCT-3ʹ shows a melt-
ing point of 50.4 °C. We considered that the 
most likely origin of the destabilisation was 
a mismatch resulting from the presence of 
the metal-containing unit and tested this in 
two ways. Firstly, we prepared a ruthenaoli-
gonucleotide IV with a shorter OCH2CH2O 
spacer between the tpy and the first nucleotide 
and found for the sequence analogous to I a 
melting point of 34.2 °C – identical within 
experimental error. Secondly, we introduced 
a redundant triplet into the RNA complemen-
tary strand at the site of metallation using the 
sequence 3ʹ-AAA-AAG-AGA-AAA-GAG-
AGA-5ʹand found a slight stabilization of I 
(35.1 °C) and a destabilisation of IV (30.2 
°C). With a longer RNA complementary se-
quence 3ʹ-AAA-AAG-AGA-AAAA-GAG-
AGA-5ʹthe melting points of both I and IV 
were slightly lowered. 
We are currently investigating the photo-
chemical and photophysical properties of 
these and related ruthenated systems.
Self-assembly of Bioconstructs with 
Labile Metal Ions
In the systems described above, we have 
used kinetically inert metal centres to con-
struct stable metallated species which are 
stable both to biological and to chemical re-
action conditions. A contrasting approach 
involves the use of labile metal ions to link 
together nucleic acids functionalised in the 
terminal positions to give new extended se-
quences. We are interested in this as a meth-
odology for the construction of a comple-
mentary sequence for a target strand from a 
library of ‘half-sequences’ each functional-
ised with a metal-binding domain appropri-
ate to the selected metal ion.
Our preliminary work has centred upon 
6,6ʹ-disubstituted 2,2ʹ-bipyridine or 2,9-di-
functionalised 1,10-phenanthroline ligands 
which are optimised for the binding and 
stabilisation of copper(I) in aqueous condi-
tions. The choice of copper(I) is predicated 
upon the easy detection (spectrophotomet-
ric, luminescence, electrochemical) of the 
newly formed {CuIL2} motif. The initial 
concept is simple: a library of function-
alised sequences A, B,..ni will react with 
copper(I) to form a new library of complex- 
self-assembly step to generate an unnatural 
palindromic sequence such as{CuI(3ʹ-A)(3ʹ 
-C)} which has no natural complementary 
Watson-Crick sequence (Fig. 4). Only by 
preparing unnatural nucleic acids with a 
direction inversion (3ʹ-A*C*-3ʹ with a 5ʹ,5ʹ 
linkage of the A* and C* sections) could 
a genuinely complementary nucleotide se-
quence be achieved. However, a much more 
interesting possibility exists that we are 
currently exploring. Consider a library of 
complexes prepared from the complemen-
tary functionalised sequences 3ʹ-A, 5ʹ-A*: 
this will give a library of three complexes 
{CuI(3ʹ-A)(3ʹ-A)}, {CuI(3ʹ-A)(5ʹ-A*)}, 
{CuI(5ʹ-A*)(5ʹ-A*)}, which are expected 
to give just two complementary hybrids, 
[{CuI(3ʹ-A)(3ʹ-A)}•{CuI(5ʹ-A*)(5ʹ-A*)}] 
and [{CuI(3ʹ-A)(5ʹ-A*)}•{CuI(5ʹ-A*)(3ʹ-
A)}] in a statistical ratio of 1:4.
Of more direct relevance to applications 
of this methodology, is the binding of one 
Fig. 3. The synthesis of in-chain ruthenaoligonucleotides at a polystyrene/long chain alkylamine 
(35-40 μmol/g) solid phase: i) tetrazole; ii) coupling on support; iii) tert-butyl hydroperoxide; iv) 
HOCH2CH2OH, N-ethylmorpholine, acetic acid, pH 7; v) deprotection of next residue (DMT-protected, 
CCl3CO2H). The final sequence is removed from the support by treatment with aqueous ammonia 
solution. The inset shows a typical capillary electrophoresis trace for HPLC purified material. 
es {CuI(L1)(L2)} comprising       compo-
nents in statistical amounts. If the sequenc-
es A, B ... ni are complementary to A*, B* 
... ni* then the target sequence, say A*C*, 
will only be complementary to one compo-
nent of the library of complexes, {CuIAC}. 
As copper(I) complexes are labile, the for-
mation of the duplex [A*C*•{CuIAC}] 
will result in a redistribution of the library 
to concentrate the A and C components in 
{CuIAC} – in other words, this is a metal-
centred dynamic combinatorial library. The 
practice is complicated by the fact that the 
oligonucleotides can be functionalised at 
the 3ʹ or 5ʹ ends, e.g. 3ʹ-A or 5ʹ-A (where 
3ʹ-A refers to the site of attachment of the 
metal-binding domain) and only the result-
ing chimera complex {CuI(3ʹ-A)(5ʹ-C)} 
will be complementary to 3ʹ-A*C*-5ʹ.
This latter constraint has a number of 
interesting consequences. Firstly, by taking 
any single sequence, it is possible in a single 
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sequence to a support. If an A sequence 
is, for example, attached to the support 
through the 3ʹ end, then we effectively have 
a surface-immobilised S-5ʹ-A fragment. It 
is only necessary to have copper(I) and 3ʹ-
functionalised solution species to give sur-
face immobilised species that run uniquely 
in a non-palindromic 3ʹ to 5ʹ direction. This 
is the basis of our current approach to sur-
face tethered species.
An example of strategy in action is pre-
sented in Fig. 4. The asymmetric ligand 
2-hydroxymethyl-9-methyl-1,10-phenan-
throline I is prepared by the conversion 
of 2,9-dimethyl-1,10-phenanthroline to 
its N-oxide and subsequent heating with 
acetic anhydride and hydrolysis of the 
intermediate 2-acetoxymethyl-9-methyl-
1,10-phenanthroline. This was converted 
to the phosphoramidite II in 55% yield 
under standard conditions which was then 
coupled with 3ʹ-CGCCGCAGTTATT-5ʹ at-
tached to Universal Solid Support II by the 
3ʹ end under standard reaction conditions to 
give the conjugate IV. The resultant conju-
gate exhibits a parent ion at m/z 4287 in its 
MALDI-TOF mass spectrum correspond-
ing to {IV + 2Na+}. The palindromic com-
plex [Cu(IV)2]
n+ is obtained directly by the 
reaction of [Cu(MeCN)4]
+ salts with IV in 
aqueous acetonitrile. 
We are currently investigating the prep-
aration of artificial dynamic combinatorial 
libraries of self-assembled metalloligonu-
cleotides and developing surface tethered 
species for use in DNA-chip methodology.
Conclusions
The modification of nucleotides through 
the covalent attachment of metal complexes 
or of metal-binding domains is a powerful 
technique for the construction of bioinor-
ganic conjugates with novel and designed 
redox, chemical or photophysical proper-
ties. A judicious choice of metal and oxi-
dation state allows the strategy to be based 
upon self-assembly at labile metal species 
or upon linear synthesis utilising kinetically 
inert metal centres.
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